ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, March 28, 2023 at the virtual BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines.

About ReCode Therapeutics

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005002/en/